Patrick O'Hearn Email & Phone Number

Boston, Ma, Us

Cambridge, Ma, Us

Cambridge, Ma, Us

Cambridge, Ma, Us

Cambridge, Ma, Us

Development, performance, sample analysis, and data interpretation/reporting for internal ADME assays including accurate mass determination, solubility, plasma stability, plasma protein binding, metabolic stability in microsomes and hepatocytes, CYP450 inhibition, and CYP450 reaction phenotyping using recombinant CYPs.Responsible for managing outsourced in vitro ADME and in vivo pharmacokinetic studies. Provide input for both internal and outsourced pharmacokinetic studies and perform sample analysis for internal programs.Responsible for managing data upload for internal/external ADME studies into database so that research groups can view results for compounds of interests for a given program.Serve as DMPK project representative on early discovery drug program providing guidance for ADME study design and potential issues. Utilize DiscoveryQuant Optimize/Analyze software to improve efficiency of analytical method development, sample analysis, and results reporting for compounds being tested in ADME screening assays.Contribute mass spectrometry support for project teams including experiments such as drug quantitation and tissue extraction of analytes of interest using UPLC-MS/MS and UPLC-HRMS.Point person for equipment training as well as routine maintenance and troubleshooting for open access analytical HPLC-MS and mass-directed purification HPLC-MS.

Cambridge, Massachusetts, Us

DMPK project lead on an internal early discovery program where I provided guidance on in vitro and in vivo study design including in vitro ADME assays (including hepatocyte/microsome/plasma stability and protein binding) and in vivo PK.Designed and conducted CYP450 induction assay using cryopreserved hepatocytes and suitable LC-MS/MS analytical methods for FDA recommended probe substrates for CYP1A, CYP2B, and CYP3A, and used these data to assess compounds in early discovery to help understand potential DDI liabilities. Added secondary cell viability endpoint (Cell Titer Glo) to the assay in order to increase utility of each experiment.Assessed direct and metabolism-dependent CYP450 inhibition of proprietary compounds. Also performed assay development for the assessment of CYP2C8 inhibition.Performed in vitro experiments in support of drug discovery including compound metabolic stability (suspension hepatocytes, microsomes), protein binding, and plasma stability.Brought BSEP vesicle-based transporter assay in-house and developed LC-MS/MS analytical methods.Pharmacokinetic study design input, sample analysis, and data interpretation in various matrices (including plasma, lung, liver, tumor tissue) in support of multiple early discovery programs. Data analysis performed using Analyst and Phoenix WinNonLin.Performed compound optimization, method development, mobile phase preparation, sample analysis, and system maintenance/troubleshooting on LC-MS/MS systems. Managed Northeastern University co-op student during a 6-month internship with work aimed at adding assays to the DMPK group such as a BSEP vesicle based transport assay.Served as a DMPK group representative on the Laboratory Safety Committee as well as on the Emergency Response Team (1st aid and CPR certified)

Cambridge, Massachusetts, Us

Cambridge, Massachusetts, Us

Cambridge, Massachusetts, Us

-Northeastern University Co-op program (full time June - December 2008, part time January- June 2009)

Cambridge, Massachusetts, Us

Performing assays in support of Merrimack's lead oncology drug, MM-121. Duties included cell culture work as well as laboratory work including cell transformation and ELISA.